ExPEC9V

Phase 3Biologic

Johnson & Johnson

ExPEC9V is one of 55 biologic programs targeting Influenza. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) PreventionCompleted

Urinary Tract InfectionActive, not recruiting

InfluenzaPhase 3

Active, not recruiting

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) PreventionPhase 3

Completed

Urinary Tract InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

ExPEC9V

Johnson & Johnson

Phase 3

1 2

Fluzone

Sanofi

Preclinical

16 3

Fluzone

GSK

Preclinical

37 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza1 trial

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06134804·959 enrolled

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention1 trial

Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04899336·17,797 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ExPEC9V. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ExPEC9V compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ExPEC9V. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

ExPEC9V

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza1 trial

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention1 trial

References

Drug Info

Quick Facts

Related News